Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2023 · 10-Q
Revenue$5.14M$5.14M+5.6% vs Q3 2022 Net Income-$5.67M-$5.67MN/M vs Q3 2022 EPS Diluted-$0.13-$0.13N/M vs Q3 2022 Gross Profit$1,296,867−26.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,981,674N/M Free Cash Flowderived-$1,981,674N/M Margins · derivedGross margin25.2%−11.1 pt vs Q3 2022
Operating margin-84.0%+20.9 pt vs Q3 2022
Net margin-110.2%−4.6 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end